Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11812MR)

This product GTTS-WQ11812MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Breast Cancer, Colorectal Cancer (CRC), Non-Small Cell Lung Cancers (NSCLC), Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11812MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ183MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ2876MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ8902MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ12307MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ679MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ9291MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ1567MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ12606MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW